PDCD1 and acute kidney injury: In a review by Manohar et al. in 2019 on programmed cell death protein 1 (PD‐1) inhibitor, 11 482 patients enrolled into the study demonstrated a similar pooled incidence of AKI with PD‐1 inhibitors, total AKI incidence was 2.2%, the pooled incidence of AKI with nivolumab treatment was 2.3% and with pembrolizumab was 2.0%.6